The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry

Stephen O'Neill; Joan Sweeney; Chris C Patterson; Andrew Menzies-Gow; Rob Niven; Adel H Mansur; Christine Bucknall; Rekha Chaudhuri; Neil C Thomson; Chris E Brightling; Ciaran O'Neill; Liam G Heaney; British Thoracic Society Difficult Asthma Network

doi:10.1136/thoraxjnl-2013-204114

The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry

Stephen O'Neill, Joan Sweeney, Chris C Patterson, Andrew Menzies-Gow, Rob Niven, Adel H Mansur, Christine Bucknall, Rekha Chaudhuri, Neil C Thomson, Chris E Brightling, Ciaran O'Neill, Liam G Heaney, British Thoracic Society Difficult Asthma Network

Research output: Contribution to journal › Article › peer-review

155 Citations (Scopus)

Abstract

Severe refractory asthma poses a substantial burden in terms of healthcare costs but relatively little is known about the factors which drive these costs. This study uses data from the British Thoracic Society Difficult Asthma Registry (n=596) to estimate direct healthcare treatment costs from an National Health Service perspective and examines factors that explain variations in costs. Annual mean treatment costs among severe refractory asthma patients were £2912 (SD £2212) to £4217 (SD £2449). Significant predictors of costs were FEV1% predicted, location of care, maintenance oral corticosteroid treatment and body mass index. Treating individuals with severe refractory asthma presents a substantial cost to the health service.

Original language	English
Pages (from-to)	376-378
Number of pages	3
Journal	Thorax
Volume	70
Issue number	4
Early online date	10 Jun 2014
DOIs	https://doi.org/10.1136/thoraxjnl-2013-204114
Publication status	Published - Apr 2015

Keywords

Adult
Anti-Asthmatic Agents
Asthma
Body Mass Index
Drug Costs
Female
Forced Expiratory Volume
Glucocorticoids
Great Britain
Health Care Costs
Health Services
Health Services Research
Humans
Male
Middle Aged
Registries
State Medicine

Access to Document

10.1136/thoraxjnl-2013-204114

Ciaran O'Neill
- Ciaran.ONeillqub.acuk
- ciaran.oneillnuigalwayie
- School of Medicine, Dentistry and Biomedical Sciences - Professor, Honorary Professor
- Centre for Public Health
Person: Honorary, Academic

Cite this

O'Neill, S., Sweeney, J., Patterson, C. C., Menzies-Gow, A., Niven, R., Mansur, A. H., Bucknall, C., Chaudhuri, R., Thomson, N. C., Brightling, C. E., O'Neill, C., Heaney, L. G., & British Thoracic Society Difficult Asthma Network (2015). The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax, 70(4), 376-378. https://doi.org/10.1136/thoraxjnl-2013-204114

@article{abceb47479924c21ad2852a3725c165f,

title = "The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry",

abstract = "Severe refractory asthma poses a substantial burden in terms of healthcare costs but relatively little is known about the factors which drive these costs. This study uses data from the British Thoracic Society Difficult Asthma Registry (n=596) to estimate direct healthcare treatment costs from an National Health Service perspective and examines factors that explain variations in costs. Annual mean treatment costs among severe refractory asthma patients were £2912 (SD £2212) to £4217 (SD £2449). Significant predictors of costs were FEV1% predicted, location of care, maintenance oral corticosteroid treatment and body mass index. Treating individuals with severe refractory asthma presents a substantial cost to the health service.",

keywords = "Adult, Anti-Asthmatic Agents, Asthma, Body Mass Index, Drug Costs, Female, Forced Expiratory Volume, Glucocorticoids, Great Britain, Health Care Costs, Health Services, Health Services Research, Humans, Male, Middle Aged, Registries, State Medicine",

author = "Stephen O'Neill and Joan Sweeney and Patterson, {Chris C} and Andrew Menzies-Gow and Rob Niven and Mansur, {Adel H} and Christine Bucknall and Rekha Chaudhuri and Thomson, {Neil C} and Brightling, {Chris E} and Ciaran O'Neill and Heaney, {Liam G} and {British Thoracic Society Difficult Asthma Network}",

year = "2015",

month = apr,

doi = "10.1136/thoraxjnl-2013-204114",

language = "English",

volume = "70",

pages = "376--378",

journal = "Thorax",

issn = "0040-6376",

publisher = "BMJ Publishing Group",

number = "4",

}

O'Neill, S, Sweeney, J, Patterson, CC, Menzies-Gow, A, Niven, R, Mansur, AH, Bucknall, C, Chaudhuri, R, Thomson, NC, Brightling, CE, O'Neill, C , Heaney, LG & British Thoracic Society Difficult Asthma Network 2015, 'The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry', Thorax, vol. 70, no. 4, pp. 376-378. https://doi.org/10.1136/thoraxjnl-2013-204114

TY - JOUR

T1 - The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry

AU - O'Neill, Stephen

AU - Sweeney, Joan

AU - Patterson, Chris C

AU - Menzies-Gow, Andrew

AU - Niven, Rob

AU - Mansur, Adel H

AU - Bucknall, Christine

AU - Chaudhuri, Rekha

AU - Thomson, Neil C

AU - Brightling, Chris E

AU - O'Neill, Ciaran

AU - Heaney, Liam G

AU - British Thoracic Society Difficult Asthma Network

PY - 2015/4

Y1 - 2015/4

N2 - Severe refractory asthma poses a substantial burden in terms of healthcare costs but relatively little is known about the factors which drive these costs. This study uses data from the British Thoracic Society Difficult Asthma Registry (n=596) to estimate direct healthcare treatment costs from an National Health Service perspective and examines factors that explain variations in costs. Annual mean treatment costs among severe refractory asthma patients were £2912 (SD £2212) to £4217 (SD £2449). Significant predictors of costs were FEV1% predicted, location of care, maintenance oral corticosteroid treatment and body mass index. Treating individuals with severe refractory asthma presents a substantial cost to the health service.

AB - Severe refractory asthma poses a substantial burden in terms of healthcare costs but relatively little is known about the factors which drive these costs. This study uses data from the British Thoracic Society Difficult Asthma Registry (n=596) to estimate direct healthcare treatment costs from an National Health Service perspective and examines factors that explain variations in costs. Annual mean treatment costs among severe refractory asthma patients were £2912 (SD £2212) to £4217 (SD £2449). Significant predictors of costs were FEV1% predicted, location of care, maintenance oral corticosteroid treatment and body mass index. Treating individuals with severe refractory asthma presents a substantial cost to the health service.

KW - Adult

KW - Anti-Asthmatic Agents

KW - Asthma

KW - Body Mass Index

KW - Drug Costs

KW - Female

KW - Forced Expiratory Volume

KW - Glucocorticoids

KW - Great Britain

KW - Health Care Costs

KW - Health Services

KW - Health Services Research

KW - Humans

KW - Male

KW - Middle Aged

KW - Registries

KW - State Medicine

U2 - 10.1136/thoraxjnl-2013-204114

DO - 10.1136/thoraxjnl-2013-204114

M3 - Article

C2 - 24917087

SN - 0040-6376

VL - 70

SP - 376

EP - 378

JO - Thorax

JF - Thorax

IS - 4

ER -

The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry

Abstract

Keywords

Access to Document

Fingerprint

Profiles

Ciaran O'Neill

Cite this